| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | New England Journal of Medicine | 2013 | 3.8K |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 2.3K |
| Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2017 | 2K |
| Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | New England Journal of Medicine | 2018 | 1.3K |
| First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 1.2K |
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | New England Journal of Medicine | 2016 | 975 |
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Journal of Clinical Oncology | 2015 | 859 |
| Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial | Lancet Oncology, The | 2016 | 818 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Lancet Oncology, The | 2016 | 783 |
| Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | New England Journal of Medicine | 2019 | 672 |
| Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer | Journal of Clinical Oncology | 2016 | 601 |
| Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) | Journal of Clinical Oncology | 2017 | 495 |
| Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) | Cancer Discovery | 2017 | 475 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors | Cancer Discovery | 2015 | 460 |
| CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma | New England Journal of Medicine | 2018 | 456 |
| Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study | Journal of Clinical Oncology | 2016 | 420 |
| Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study | Journal of Clinical Oncology | 2017 | 415 |
| The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients | Cancer Discovery | 2020 | 413 |
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials | European Journal of Cancer | 2012 | 404 |
| Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study | Blood | 2014 | 403 |
| Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | New England Journal of Medicine | 2020 | 396 |
| Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Journal of Clinical Oncology | 2013 | 391 |
| Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma | Nature Communications | 2016 | 387 |
| Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study | Journal of Clinical Oncology | 2018 | 381 |
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Lancet Oncology, The | 2012 | 372 |
